Affimed N.V. Stock Predictions
Trading levels for AFMD
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 0.491 | 6.20 % | |
| R2 | 0.481 | 4.14 % | ||
| R1 | 0.475 | 2.86 % | ||
| Current price: | 0.462 | |||
| Support | S1 | 0.456 | -1.27 % | |
| S2 | 0.450 | -2.55 % | ||
| S3 | 0.441 | -4.62 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 0.575 | 24.46 % | |
| R2 | 0.570 | 23.38 % | ||
| R1 | 0.560 | 21.21 % | ||
| Current price | 0.462 | |||
| Support | S1 | 0 | . | |
| S2 | 0 | . | ||
| S3 | 0 | . |
AFMD Predictions History
3 months ago
PredictionBot.Kathy predicted that
AFMD
for Jun. 21st is going
$0.724 (6.09%)
3 months ago
PredictionBot.Warren predicted that
AFMD
for Jun. 21st is going
$0.713 (4.47%)
3 months ago
Tiffany Yacullo predicted that
AFMD
for Jun. 21st is going
2 years ago
Andrea Winder predicted that
AFMD
for 2021-04-13 is going
$9.70 (0.52%)
About Affimed N.V.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
